Free Trial

Regulus Therapeutics (RGLS) Competitors

Regulus Therapeutics logo
$8.16 0.00 (0.00%)
As of 06/25/2025

RGLS vs. LGND, BCRX, FOLD, CLDX, INVA, DVAX, MNKD, OPK, NVAX, and GERN

Should you be buying Regulus Therapeutics stock or one of its competitors? The main competitors of Regulus Therapeutics include Ligand Pharmaceuticals (LGND), BioCryst Pharmaceuticals (BCRX), Amicus Therapeutics (FOLD), Celldex Therapeutics (CLDX), Innoviva (INVA), Dynavax Technologies (DVAX), MannKind (MNKD), OPKO Health (OPK), Novavax (NVAX), and Geron (GERN). These companies are all part of the "biotechnology" industry.

Regulus Therapeutics vs. Its Competitors

Ligand Pharmaceuticals (NASDAQ:LGND) and Regulus Therapeutics (NASDAQ:RGLS) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends, media sentiment and earnings.

Ligand Pharmaceuticals has a beta of 0.84, suggesting that its stock price is 16% less volatile than the S&P 500. Comparatively, Regulus Therapeutics has a beta of 0.35, suggesting that its stock price is 65% less volatile than the S&P 500.

Ligand Pharmaceuticals has higher revenue and earnings than Regulus Therapeutics. Ligand Pharmaceuticals is trading at a lower price-to-earnings ratio than Regulus Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ligand Pharmaceuticals$167.13M13.20-$4.03M-$7.12-16.07
Regulus TherapeuticsN/AN/A-$46.36M-$0.73-11.18

Ligand Pharmaceuticals currently has a consensus target price of $146.14, indicating a potential upside of 27.76%. Regulus Therapeutics has a consensus target price of $8.50, indicating a potential upside of 4.17%. Given Ligand Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Ligand Pharmaceuticals is more favorable than Regulus Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ligand Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
3.00
Regulus Therapeutics
0 Sell rating(s)
5 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.29

Regulus Therapeutics has a net margin of 0.00% compared to Ligand Pharmaceuticals' net margin of -73.07%. Ligand Pharmaceuticals' return on equity of -7.83% beat Regulus Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Ligand Pharmaceuticals-73.07% -7.83% -6.92%
Regulus Therapeutics N/A -57.53%-53.26%

In the previous week, Ligand Pharmaceuticals had 7 more articles in the media than Regulus Therapeutics. MarketBeat recorded 7 mentions for Ligand Pharmaceuticals and 0 mentions for Regulus Therapeutics. Ligand Pharmaceuticals' average media sentiment score of 0.92 beat Regulus Therapeutics' score of 0.00 indicating that Ligand Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Ligand Pharmaceuticals Positive
Regulus Therapeutics Neutral

91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. Comparatively, 92.4% of Regulus Therapeutics shares are owned by institutional investors. 7.0% of Ligand Pharmaceuticals shares are owned by insiders. Comparatively, 4.4% of Regulus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Ligand Pharmaceuticals beats Regulus Therapeutics on 11 of the 15 factors compared between the two stocks.

Get Regulus Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for RGLS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RGLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RGLS vs. The Competition

MetricRegulus TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$564.92M$2.43B$5.53B$9.02B
Dividend YieldN/A1.78%5.22%3.99%
P/E Ratio-11.189.1527.7920.25
Price / SalesN/A680.43426.06119.26
Price / CashN/A21.7726.2128.59
Price / Book6.974.558.045.65
Net Income-$46.36M$31.26M$3.18B$249.15M
7 Day PerformanceN/A2.98%2.89%2.91%
1 Month Performance-0.73%3.46%1.67%4.11%
1 Year Performance391.57%0.77%34.53%20.98%

Regulus Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RGLS
Regulus Therapeutics
1.5861 of 5 stars
$8.16
flat
$8.50
+4.2%
N/A$564.92MN/A-11.1830Gap Up
LGND
Ligand Pharmaceuticals
4.8114 of 5 stars
$113.68
-0.4%
$146.14
+28.6%
+35.6%$2.20B$167.13M-15.9780
BCRX
BioCryst Pharmaceuticals
4.4714 of 5 stars
$8.96
-4.3%
$16.89
+88.5%
+37.2%$1.96B$450.71M-34.46530
FOLD
Amicus Therapeutics
3.694 of 5 stars
$5.73
-3.4%
$16.22
+183.1%
-38.6%$1.83B$528.29M-63.66480
CLDX
Celldex Therapeutics
3.0709 of 5 stars
$20.35
+0.3%
$50.11
+146.2%
-38.1%$1.35B$7.02M-7.54150
INVA
Innoviva
3.8999 of 5 stars
$20.09
+0.7%
$55.00
+173.8%
+17.4%$1.25B$358.71M-19.89100
DVAX
Dynavax Technologies
4.3926 of 5 stars
$9.92
+0.1%
$24.00
+141.9%
-8.6%$1.19B$277.25M-19.08350Positive News
MNKD
MannKind
2.5282 of 5 stars
$3.74
-0.5%
$10.33
+176.3%
-29.7%$1.14B$285.50M37.40400
OPK
OPKO Health
4.449 of 5 stars
$1.32
flat
$2.75
+108.3%
+6.7%$1.05B$713.10M-18.852,997
NVAX
Novavax
4.497 of 5 stars
$6.30
-1.1%
$17.00
+169.8%
-42.9%$1.03B$682.16M2.381,990
GERN
Geron
2.8523 of 5 stars
$1.41
-5.4%
$5.06
+259.0%
-68.5%$949.01M$76.99M-6.7170

Related Companies and Tools


This page (NASDAQ:RGLS) was last updated on 7/7/2025 by MarketBeat.com Staff
From Our Partners